MOLNUPIRAVIR

MOLNUPIRAVIR: Molnupiravir is an antiviral drug that is used for the treatment of COVID-19. It is an orally administered medication that works by inhibiting the replication of the SARS-CoV-2 virus.

The mechanism of action of molnupiravir involves interfering with the viral replication process. After being metabolized within the body, it is converted into its active form called N4-hydroxycytidine. This active form is incorporated into the viral RNA during its synthesis, causing mutations that can lead to errors in replication. These errors ultimately result in non-functional viral RNA, preventing the virus from multiplying and spreading within the body.

The recommended dose of molnupiravir for the treatment of COVID-19 is 800 mg (four capsules of 200 mg each) taken orally every 12 hours for a total of five days. It is important to follow the prescribed dosing schedule and complete the full course of treatment unless otherwise instructed by a healthcare professional.

As with any medication, molnupiravir may cause side effects. Some common side effects include nausea, diarrhea, headache, fatigue, and rash. It is important to consult a healthcare provider if any side effects are severe or persist for an extended period.

It is worth noting that molnupiravir is still undergoing clinical trials and has not been approved by regulatory authorities in several countries. Therefore, it is only available for use in certain nations under emergency use authorizations or similar pathways. Patients should consult their healthcare provider regarding the availability and appropriate use of molnupiravir for COVID-19 treatment.